Trial Outcomes & Findings for Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors (NCT NCT00848185)
NCT ID: NCT00848185
Last Updated: 2018-06-26
Results Overview
VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG
Recruitment status
COMPLETED
Target enrollment
96 participants
Primary outcome timeframe
1 year
Results posted on
2018-06-26
Participant Flow
Participant milestones
| Measure |
Antagonist Trigger With aGnRH
Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
|
Antagonist Trigger With hCG
Protocol with antagonist and hCG to trigger oocyte maturation
|
Long Protocol hCG
Long Protocol with hCG to trigger oocyte maturation
|
|---|---|---|---|
|
Overall Study
STARTED
|
32
|
32
|
32
|
|
Overall Study
COMPLETED
|
32
|
32
|
32
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Baseline characteristics by cohort
| Measure |
Antagonist-hCG to Trigger
n=32 Participants
Protocol with antagonist and hCG to trigger oocyte maturation
|
Antagonist-aGnRH to Trigger
n=32 Participants
Protocol with antagonist and 0.2 mg triptorelin to trigger oocyte maturation
|
Long Protocol-hCG
n=32 Participants
Long Protocol and hCG to trigger oocyte maturation
|
Total
n=96 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
27.2 years
STANDARD_DEVIATION 3.5 • n=5 Participants
|
23.7 years
STANDARD_DEVIATION 3.9 • n=7 Participants
|
24.5 years
STANDARD_DEVIATION 3.7 • n=5 Participants
|
25.1 years
STANDARD_DEVIATION 3.7 • n=4 Participants
|
|
Sex: Female, Male
Female
|
32 Participants
n=5 Participants
|
32 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
96 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
32 Participants
n=5 Participants
|
32 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
96 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Region of Enrollment
Spain
|
32 participants
n=5 Participants
|
32 participants
n=7 Participants
|
32 participants
n=5 Participants
|
96 participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 1 yearVEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG
Outcome measures
| Measure |
Antagonist-hCG Levels of VEGF
n=32 Participants
Levels of VEGF in folicular fluid of patients with antagonist protocol anf hCG for triggering
|
Antagonist-aGnRH Levels of VEGF
n=32 Participants
Levels of VEGF in folicular fluid of patients with antagonist protocol and aGnRH for triggering
|
Long Protocol- hCG
n=32 Participants
Levels of VEGF in folicular fluid of patients with long protocol anf hCG for triggering
|
|---|---|---|---|
|
VEGF Protein and mRNA Levels
|
1395 pg/ml
Standard Deviation 284
|
1069 pg/ml
Standard Deviation 354
|
1666 pg/ml
Standard Deviation 55
|
Adverse Events
GnRH Antagonist - hCG Trigger
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
GnRH Antagonist Triptorelin Trigger
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Long Protocol - hCG Trigger
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place